You are here

BCRF Grantee Since

2005

Area(s) of Focus

Geoffrey M. Wahl, PhD

Professor, Gene Expression Laboratory
The Salk Institute
La Jolla, CA

Current Research

Dr. Wahl’s BCRF research is focused on understanding the properties of stem-like cells in triple negative breast cancer, a very aggressive type of breast cancer that is so named because the tumor cells lack the estrogen and progesterone receptors and the Her2 protein. Stem cells are the cells from which tissues are derived during development. They are also believed to be the cells that give rise to tumors and promote tumor progression. Work in Dr. Wahl’s group showed that genes expressed in mammary stem cells (MaSCs) show significant similarities to those expressed in triple negative breast cancers. They are now characterizing these cells further in an attempt to identify molecular targets for the development of new therapeutics that can provide an alternative to, or be used in combination with, chemotherapy in patients whose cancers show a mammary stem cell signature. Dr. Wahl’s team is in the process of culturing these cells in the laboratory to identify the molecules and pathways that contribute to stem-ness. BCRF funding has made it possible for Dr. Wahl and his group to develop a novel experimental system that will greatly facilitate the identification of the genes needed to maintain MaSCs in the stem cell state, and will also enable them to study factors such as obesity, age, and genetic background on the development of MaSCs and their persistence in normal breast development.

Bio

Geoffrey M. Wahl, the Daniel and Martina Lewis Chair in the Gene Expression Laboratory, is a Professor at the Salk Institute. Wahl’s lab is studying the cells that originate and perpetuate cancers, the conditions that lead to cancer progression and metastasis, and why tumors become therapy resistant. Wahl’s early work involved uncovering the mechanisms that lead to the most common forms of genetic instability in human cancers, including those often seen in the highly aggressive, basal-like group of triple negative breast cancers. BCRF funds have been used to discern the nature of the cells that originate or perpetuate basal-like breast cancers. Wahl’s lab found that mutations in the p53 gene, the most commonly mutated gene in basal-like breast cancer, increases the chances that a fully mature cell can "reprogram" into a more primitive "stem-like" cell. His lab also found that these primitive cells have strong similarities to the earliest stem cells identifiable during breast development, which they call fetal mammary stem cells. BCRF funding is enabling Wahl’s lab to characterize the pathways essential for the growth and survival of these cells, as he expects these pathways will be important for perpetuation of basal-like breast cancers. Wahl’s lab is also identifying molecules useful for tracking these cells in the body. Their hope is that these approaches will lead to development of new molecularly targeted therapeutics and diagnostic tools to provide alternatives, or additions, to chemotherapy, currently the only type of drug therapy for patients with triple negative breast cancer.